GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Total Receivables

Dianthus Therapeutics (Dianthus Therapeutics) Total Receivables : $0.88 Mil (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Total Receivables?

Dianthus Therapeutics's Total Receivables for the quarter that ended in Mar. 2024 was $0.88 Mil.


Dianthus Therapeutics Total Receivables Historical Data

The historical data trend for Dianthus Therapeutics's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Total Receivables Chart

Dianthus Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Total Receivables
1.48 5.64 0.48

Dianthus Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Total Receivables Get a 7-Day Free Trial 5.64 - 0.75 0.48 0.88

Dianthus Therapeutics Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables


Dianthus Therapeutics Total Receivables Related Terms

Thank you for viewing the detailed overview of Dianthus Therapeutics's Total Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.


Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Traded in Other Exchanges
Address
7 Times Square, 43rd Floor, New York, NY, USA, 10036
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines